Clinical Trial Results: Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating recombinant EphB4-HSA with azacitidine or decitabine in relapsed/refractory MDS, CMML, or AML after hypomethylating agent treatment; tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Decitabine (Decitabine)
• Recombinant EphB4-HSA fusion protein (EphB4-HSA fusion protein)

Snippet

Sponsor: University of Southern California | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2026-06-08